Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Sestrin2
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intranasal, Intraperitoneal, Intravenous
01
Overview
Recombinant Sestrin2 is a recombinant form of the stress-inducible protein Sestrin2 (SESN2). Sestrin2 is a highly conserved antioxidant protein that plays a critical role in maintaining cellular homeostasis under various stress conditions, including oxidative stress, hypoxia, and endoplasmic reticulum (ER) stress. It acts as a negative regulator of mammalian target of rapamycin complex 1 (mTORC1) and an activator of AMP-activated protein kinase (AMPK). In preclinical research, recombinant Sestrin2 has been investigated for its potential to ameliorate oxidative stress, mitochondrial damage, and apoptosis in models of contrast-induced acute kidney injury (CI-AKI), neonatal hypoxic-ischemic encephalopathy (HIE), and subarachnoid hemorrhage (SAH). It is primarily utilized as a research-use-only (RUO) laboratory reagent.
- Other names
- recombinant human Sestrin2recombinant Sestrin-2rh-sestrin2rh-sestrin-2rh-sestrin 2rp-Sestrin2rp-Sestrin-2rp-Sestrin 2
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)KEAP1 (Kelch-like ECH-associated protein 1)SQSTM1 (Sequestosome-1)
Beyond the preview
Go deeper on recombinant Sestrin2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Sestrin2.